Sarepta Therapeutics Appoints Michael Chambers and Kathryn Boor, Ph.D., to Its Board of Directors
yahoo.com
news
2022-06-02 20:05:00

Sarepta Therapeutics, Inc.

CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointments of Michael Chambers and Kathryn Boor, Ph.D., to its Board of Directors. Both Mr. Chambers and Dr. Boor bring distinct and invaluable experience to the Sarepta board that will help guide the company on its mission to change the course of life-threatening rare diseases.



'We're pleased to welcome two new board members whose participation will contribute to the realization of Sarepta's strategic vision to create transformative therapies for patients with rare diseases,' said M.
